nimesulide
Small moleculeexperimental
Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) with pain medication and fever reducing properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis, and primary dysmenorrhoea in adolescents and adults above 12 years old. — Wikipedia
Clinical trial activity
11 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
3
Earliest trial started Aug 1, 2001 (NCT02229747)
Timeline
Indications
Approved for
Studied for
- Breast Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Dyspepsia · Phase 3
- Inflammation · Phase 3
- Neoplasms · Phase 1
- Osteoarthritis, Knee · Phase 4
- Pain · Phase 2
- Pharyngitis · Phase 4
- Respiratory Tract Infections · Phase 4
- Temporomandibular Joint Disorders · Phase 2
- Temporomandibular Joint Dysfunction Syndrome · Phase 2
Mechanism of action
- Cyclooxygenase-2INHIBITOR
PTGS2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1- Mol. weight
- 308.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNimesulide ↗
- ChEMBLCHEMBL56367 ↗
- ChEMBLCHEMBL2109016 ↗
Also known as
- 4-nitro-2-phenoxymethanesulfonanilide
- antifloxil
- aulin
- aulin
- aulin
- dulanermin
- eskaflam
- guaxan
- lizepat
- mesulid
- mesulid
- mesulide
- methanesulfonamide, n-(4-nitro-2-phenoxyphenyl)-
- nexen
- nimesil
- nimesulide
- nimesulide
- nimesulide
- nimesulide
- nimesulide
- nimesulide
- nimesulide
- nimesulide
- nimesulide
- nimsulid
- r 805
- r-805
- r-805
- r-805
- redaflam
- sulidan
- sulide
- sulidene
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06039202 | Phase 2 | Jan 31, 2024 | Holy Stone Healthcare Co., Ltd |
| NCT04609748 | Phase 2 | Nov 1, 2020 | Pomeranian Medical University |
| NCT03616574 | Phase 1 | Nov 30, 2018 | Holy Stone Healthcare Co., Ltd, University of Texas at Houston |
| NCT01670552 | Phase 3 | Feb 1, 2016 | Allergisa Pesquisa Dermato-Cosmetica LTDA, EMS S/A |
| NCT03119324 | N/A | Sep 1, 2015 | University of Roma La Sapienza |
| NCT01257126 | Phase 4 | Apr 1, 2011 | Novartis |
| NCT02922712 | Phase 4 | Mar 1, 2011 | Dr. Reddy's Laboratories, Moscow State University |
| NCT01745614 | Phase 1 | Jul 18, 2010 | GlaxoSmithKline |
| NCT01500577 | Phase 2 | Apr 1, 2005 | University of Milan |
| NCT02229747 | Phase 4 | Aug 1, 2001 | Boehringer Ingelheim |
| NCT05274204 | N/A | — | Holy Stone Healthcare Co., Ltd |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Holy Stone Healthcare Co., Ltd | For profit | 3 | 3 | 3 | 2018 |
| Allergisa Pesquisa Dermato-Cosmetica LTDA | For profit | 1 | 0 | 1 | 2016 |
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 2001 |
| Dr. Reddy's Laboratories | For profit | 1 | 1 | 1 | 2011 |
| EMS S/A | For profit | 1 | 1 | 1 | 2016 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2010 |
| Moscow State University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Novartis | For profit | 1 | 1 | 1 | 2011 |
| Pomeranian Medical University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Milan | Academic/Hospital | 1 | 1 | 1 | 2005 |
| University of Roma La Sapienza | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2018 |
12 organizations
Page 1 / 1